-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $64 Price Target

Benzinga·12/04/2024 14:34:16
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $64 price target.